Comparison of Household Transmission of Influenza Virus From Index Patients Treated With Baloxavir Marboxil or Neuraminidase Inhibitors: A Health Insurance Claims Database Study

扎那米韦 医学 奥司他韦 神经氨酸酶抑制剂 优势比 置信区间 神经氨酸酶 传输(电信) 入射(几何) 逻辑回归 内科学 病毒学 病毒 工程类 传染病(医学专业) 物理 疾病 光学 电气工程 2019年冠状病毒病(COVID-19)
作者
Takuji Komeda,Takahiro Takazono,Naoki Hosogaya,Eriko Ogura,Masakazu Fujiwara,Hideyuki Miyauchi,Yoshikazu Ajisawa,Shimpei Iwata,Hideaki Watanabe,Keiichi Honda,Yoshitake Kitanishi,Kanae Hara,Hiroshi Mukae
出处
期刊:Clinical Infectious Diseases [Oxford University Press]
卷期号:72 (11): e859-e867 被引量:14
标识
DOI:10.1093/cid/ciaa1622
摘要

Abstract Background Baloxavir marboxil (baloxavir) is expected to reduce influenza transmission by rapid reduction of viral load. The incidence of household transmission was compared between index patients (IPs) treated with baloxavir and those treated with neuraminidase inhibitors. Methods Using a Japanese claims database, the first family members with influenza diagnosis during the 2018–2019 influenza season were identified as IPs, and the diagnosis date was designated day 1. According to the anti-influenza drug dispensed to the IP, their families were classified into the oral baloxavir group and 3 controls: oral oseltamivir group (a primary control), inhaled zanamivir group, and inhaled laninamivir group. A household transmission was defined as influenza diagnosed for any non-IP family members during days 3−8. The incidence of household transmission was compared between groups using a logistic regression model adjusting backgrounds of IPs. Results The proportion of families with household transmission was 17.98% (15 226 of 84 672) in the baloxavir group and 24.16% (14 983 of 62 004) in the oseltamivir group. The covariate-adjusted odds ratio (oseltamivir/baloxavir) was 1.09 (95% confidence interval [95% CI], 1.05–1.12), which indicated significantly lower incidence in the baloxavir group. The adjusted odds ratios (controls/baloxavir) against zanamivir and laninamivir were 0.93 (95% CI, .89–.97) and 0.99 (95% CI, .96–1.02), respectively. Conclusions Baloxavir may contribute to reduction in household transmission compared with oseltamivir. In comparison between baloxavir and inhalants, a similar reduction was not shown and it might be due to unmeasured confounding by administration route differences.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
彼岸花完成签到,获得积分10
刚刚
1秒前
1秒前
创新完成签到,获得积分10
1秒前
liu95完成签到 ,获得积分10
1秒前
香精完成签到,获得积分10
1秒前
GAN完成签到,获得积分10
2秒前
最後まで给最後まで的求助进行了留言
3秒前
LLL完成签到,获得积分10
3秒前
喻明辉完成签到,获得积分10
3秒前
哑牛完成签到,获得积分10
4秒前
znn完成签到 ,获得积分10
4秒前
周bangbang发布了新的文献求助10
4秒前
chongya1完成签到,获得积分10
5秒前
科研通AI2S应助111采纳,获得10
5秒前
活力山蝶应助玉玊采纳,获得10
5秒前
优秀的枕头完成签到,获得积分10
5秒前
纯纯的秦完成签到 ,获得积分10
5秒前
6秒前
6秒前
ly发布了新的文献求助10
6秒前
笑点低蜜蜂完成签到,获得积分10
6秒前
郑偏偏完成签到,获得积分10
6秒前
david发布了新的文献求助10
6秒前
yier完成签到,获得积分10
7秒前
可爱的函函应助XXXXbb采纳,获得20
7秒前
pluto应助杨123采纳,获得10
8秒前
天天快乐应助歪哔巴布采纳,获得10
8秒前
暴躁小鸟完成签到,获得积分10
8秒前
积极的尔竹完成签到,获得积分10
8秒前
丰富山灵发布了新的文献求助10
8秒前
xuyang完成签到,获得积分10
9秒前
光亮的绮晴完成签到 ,获得积分10
9秒前
9秒前
10秒前
10秒前
必毕业发布了新的文献求助20
10秒前
11秒前
云猫完成签到 ,获得积分10
11秒前
桃桃完成签到,获得积分10
11秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3968934
求助须知:如何正确求助?哪些是违规求助? 3513835
关于积分的说明 11170238
捐赠科研通 3249167
什么是DOI,文献DOI怎么找? 1794650
邀请新用户注册赠送积分活动 875278
科研通“疑难数据库(出版商)”最低求助积分说明 804755